Literature DB >> 22370312

Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.

Iván Alvarez-Twose1, Pablo González, José Mário Morgado, María Jara-Acevedo, Laura Sánchez-Muñoz, Almudena Matito, Manuela Mollejo, Alberto Orfao, Luis Escribano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22370312     DOI： 10.1200/JCO.2011.38.9973

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  19 in total

Review 1.  The new tool "KIT" in advanced systemic mastocytosis.

Authors:  William Shomali; Jason Gotlib
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT.

Authors:  Peter Valent; Sabine Cerny-Reiterer; Gregor Hoermann; Wolfgang R Sperr; Leonhard Müllauer; Christine Mannhalter; Hubert Pehamberger
Journal:  Am J Blood Res       Date:  2014-12-15

Review 3.  Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.

Authors:  John H Baird; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 4.  Primary mast cell disorders in children.

Authors:  Ari J Fried; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

Review 5.  Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.

Authors:  Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 6.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.

Authors:  Peter Valent; Cem Akin; Dean D Metcalfe
Journal:  Blood       Date:  2016-12-28       Impact factor: 22.113

Review 7.  Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.

Authors:  Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Lawrence B Schwartz; Sigurd Broesby-Olsen; Carsten Bindslev-Jensen; Petri T Kovanen; Stephen J Galli; K Frank Austen; Daniel A Arber; Hans-Peter Horny; Michel Arock; Dean D Metcalfe
Journal:  Cancer Res       Date:  2017-03-02       Impact factor: 12.701

8.  Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.

Authors:  Eunice Ching Chan; Yun Bai; Arnold S Kirshenbaum; Elizabeth R Fischer; Olga Simakova; Geethani Bandara; Linda M Scott; Laura B Wisch; Daly Cantave; Melody C Carter; John C Lewis; Pierre Noel; Irina Maric; Alasdair M Gilfillan; Dean D Metcalfe; Todd M Wilson
Journal:  J Allergy Clin Immunol       Date:  2014-02-28       Impact factor: 10.793

Review 9.  KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.

Authors:  M Arock; K Sotlar; C Akin; S Broesby-Olsen; G Hoermann; L Escribano; T K Kristensen; H C Kluin-Nelemans; O Hermine; P Dubreuil; W R Sperr; K Hartmann; J Gotlib; N C P Cross; T Haferlach; A Garcia-Montero; A Orfao; J Schwaab; M Triggiani; H-P Horny; D D Metcalfe; A Reiter; P Valent
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528

Review 10.  Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder.

Authors:  Anindya Chatterjee; Joydeep Ghosh; Reuben Kapur
Journal:  Oncotarget       Date:  2015-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.